Cargando…

Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients

BACKGROUND: Human epidermal growth factor receptor 2 (HER2)-positive tumors are defined by protein overexpression (3+) or gene amplification using immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH), respectively. HER2-positive tumors have historically included both IHC(3+) and I...

Descripción completa

Detalles Bibliográficos
Autores principales:	Horimoto, Yoshiya, Ishizuka, Yumiko, Ueki, Yuko, Higuchi, Toru, Arakawa, Atsushi, Saito, Mitsue
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8897871/ https://www.ncbi.nlm.nih.gov/pubmed/35248011 http://dx.doi.org/10.1186/s12885-022-09351-4

Ejemplares similares

Ki67 expression and the effect of neo-adjuvant chemotherapy on luminal HER2-negative breast cancer
por: Horimoto, Yoshiya, et al.
Publicado: (2014)

Difficulty Diagnosing a Brain Tumor during Clinical Maintenance of a Complete Response to anti-HER2 Treatments for Metastatic Breast Cancer: A Case Report
por: Semba, Ryoko, et al.
Publicado: (2020)

HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
por: Morsberger, Laura, et al.
Publicado: (2022)

ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer
por: Pinhel, Isabel, et al.
Publicado: (2012)

Patterns of HER2 Gene Amplification and Response to Anti-HER2 Therapies
por: Vicario, Rocio, et al.
Publicado: (2015)

Microsatellite-Stable Radiation-Induced Angiosarcoma after Breast-Conserving Surgery: A Case Report
por: Ishizuka, Yumiko, et al.
Publicado: (2020)

Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER‐targeted therapy in HER2 amplification‐positive and HER2 mutation‐positive amplification‐negative patients
por: Liu, Binliang, et al.
Publicado: (2022)

Significance of HER2 protein expression and HER2 gene amplification in colorectal adenocarcinomas
por: Wang, Xin-Yu, et al.
Publicado: (2019)

Overexpression of HER2/HER3 and clinical feature of ovarian cancer
por: Chung, Ye Won, et al.
Publicado: (2019)

KRAS mutation in relation to HER2 overexpression/amplification in colorectal cancer
por: Bar, Julia K, et al.
Publicado: (2012)

PTEN loss and level of HER2 amplification is associated with trastuzumab resistance and prognosis in HER2-positive gastric cancer
por: Kim, Chan, et al.
Publicado: (2017)

FGFR1 Amplification and Response to Neoadjuvant Anti-HER2 Treatment in Early HER2-Positive Breast Cancer
por: Gaibar, María, et al.
Publicado: (2022)

The role of neoadjuvant her2-targeted therapies in her2-overexpressing breast cancers
por: Lemieux, J., et al.
Publicado: (2009)

Methods for preparing tissue microarray slides using xenografts with different levels of HER2 expression to standardize HER2 detection
por: Yorozu, Keigo, et al.
Publicado: (2022)

Low Level of Her-2 Locus Amplification by Fluorescent In Situ Hybridization Does Not Correlate with Her-2 Protein Overexpression by Immunohistochemistry in Barrett's Esophagus
por: Rygiel, Agnieszka M., et al.
Publicado: (2010)

Low frequency of HER2 amplification and overexpression in early onset gastric cancer
por: Moelans, Cathy B., et al.
Publicado: (2011)

Loss of HER2 Positivity after Trastuzumab in HER2-Positive Gastric Cancer: Is Change in HER2 Status Significantly Frequent?
por: Ishimine, Yu, et al.
Publicado: (2015)

Palindromic amplification of the ERBB2 oncogene in primary HER2-positive breast tumors
por: Marotta, Michael, et al.
Publicado: (2017)

The role of her2-targeted therapies in women with her2-overexpressing metastatic breast cancer
por: Dent, S., et al.
Publicado: (2009)

Clinicopathological Examination of Metaplastic Spindle Cell Carcinoma of the Breast: Case Series
por: Ishizuka, Yumiko, et al.
Publicado: (2021)

HER2-positive gastric cancer identified by serum HER2: A case report
por: SAITO, MAYUKO, et al.
Publicado: (2016)

Is HER2 amplification predictable by digital immunohistochemistry?
por: Micsik, Tamás, et al.
Publicado: (2013)

HER-2 gene amplification in human breast cancer without concurrent HER-2 over-expression
por: Luoh, Shiuh-Wen, et al.
Publicado: (2013)

Robust and accurate digital measurement for HER2 amplification in HER2 equivocal breast cancer diagnosis
por: Wang, Yuefeng, et al.
Publicado: (2017)

HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer
por: Lipton, Allan, et al.
Publicado: (2013)

HER2/positive and HER2/low in inflammatory breast cancer recurrence
por: Movchan, Oleksii Volodimirovich, et al.
Publicado: (2022)

Correlation of HER2, p95HER2 and HER3 Expression and Treatment Outcome of Lapatinib plus Capecitabine in her2-Positive Metastatic Breast Cancer
por: Han, Sae-Won, et al.
Publicado: (2012)

Granular Cell Tumor of the Breast Coexisting with Ductal Carcinoma in situ: Case Report
por: Ueki, Yuko, et al.
Publicado: (2021)

Towards comprehensive characterization of HER2 overexpression
por: Berezov, Alan, et al.
Publicado: (2006)

MicroRNA and HER2-overexpressing Cancer
por: Wang, Shizhen Emily, et al.
Publicado: (2013)

TOPOIIα and HER-2/neu overexpression/amplification in Barrett’s oesophagus, dysplasia and adenocarcinoma
por: Rossi, Elisa, et al.
Publicado: (2010)

HER2 Protein Overexpression and Gene Amplification in Plasmacytoid Urothelial Carcinoma of the Urinary Bladder
por: Kim, Bohyun, et al.
Publicado: (2016)

Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level
por: Atallah, N. M., et al.
Publicado: (2023)

HER2 Heterogeneity Is Associated with Poor Survival in HER2-Positive Breast Cancer
por: Hosonaga, Mari, et al.
Publicado: (2018)

HER2 heterogeneity is a poor prognosticator for HER2-positive gastric cancer
por: Kaito, Akio, et al.
Publicado: (2019)

The impact of HER2-directed targeted therapy on HER2-positive DCIS of the breast
por: Lewis, Gary. D., et al.
Publicado: (2021)

Molecular Basis of HER2-Targeted Therapy for HER2-Positive Colorectal Cancer
por: Yoshikawa, Ayumu, et al.
Publicado: (2022)

Anti-HER2 Drugs for the Treatment of Advanced HER2 Positive Breast Cancer
por: Stanowicka-Grada, Malwina, et al.
Publicado: (2023)

Her2 assessment using quantitative reverse transcriptase polymerase chain reaction reliably identifies Her2 overexpression without amplification in breast cancer cases
por: Zoppoli, Gabriele, et al.
Publicado: (2017)

HER2 Amplification Level Predicts Pathological Complete Response in the Neoadjuvant Setting of HER2-Overexpressing Breast Cancer: A Meta-Analysis and Systematic Review
por: Gonullu, Burak, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_j5lr263m2v2vd422a90q1kgvev